Gian Lifecare

Which are the latest news on Gian Lifecare?

Why is Gian Lifecare Ltd falling/rising?

As of 05-Sep, Gian Lifecare Ltd's stock price is at 4.82, reflecting a significant decline of -66.29% over the past year, compounded by weak fundamentals and a lack of recent financial disclosures. The company's high percentage of pledged shares and decreased investor participation further indicate challenges in its financial health.

As of 05-Sep, Gian Lifecare Ltd's stock price is falling, currently at 4.82, reflecting a change of -0.04 (-0.82%). The stock has been on a downward trend, having lost -1.23% over the last two days and showing a significant decline of -66.29% over the past year. This underperformance is compounded by weak long-term fundamentals, including a negative EBITDA of Rs. -0.04 crore and a poor EBIT to Interest ratio of 1.69, indicating challenges in servicing its debt.<BR><BR>Additionally, the company has not declared results in the last six months, which raises concerns about its financial health. The Return on Equity (ROE) is low at 9.58%, suggesting limited profitability per unit of shareholder funds. The stock's performance has also been hindered by a high percentage of pledged promoter shares, which stands at 65.08%, increasing the risk of further price declines in a falling market.<BR><BR>Investor participation has decreased, with a delivery volume drop of -44.16% against the 5-day average, indicating reduced interest from shareholders. Although the stock outperformed its sector by 0.44% today, the overall trend and the negative factors surrounding the company's financial stability contribute to its falling price.

Who are in the management team of Gian Lifecare?

The management team of Gian Lifecare includes Arun Kumar Gupta (Chairman & Managing Director), Rashika Agarwal (Non Executive Director), Umang Gupta and Abhiram Saran Agarwal (Additional Independent Directors), and Astha Chaturvedi and Vanshul Asnani (Company Secretaries).

The management team of Gian Lifecare includes the following individuals:<BR><BR>1. **Arun Kumar Gupta** - Chairman & Managing Director<BR>2. **Rashika Agarwal** - Non Executive Director<BR>3. **Umang Gupta** - Additional Independent Director<BR>4. **Abhiram Saran Agarwal** - Additional Independent Director<BR>5. **Astha Chaturvedi** - Company Secretary<BR>6. **Vanshul Asnani** - Company Secretary<BR><BR>If you need more information about their roles or the company, feel free to ask!

What does Gian Lifecare do?

Gian Lifecare Ltd is a healthcare services company specializing in diagnostic services, having acquired M/s Gian Pathology & X-Ray in 2019. As of December 2025, it reported net sales of 1 Cr and a market cap of INR 5 Cr.

Overview:<BR>Gian Lifecare Ltd operates in the healthcare services industry, specifically focusing on diagnostic services.<BR><BR>History:<BR>The company was incorporated in 2018 and registered as a Public Limited Company. It acquired the entire business of M/s Gian Pathology & X-Ray from its promoter Mr. Arun Kumar Gupta effective March 1, 2019. The latest quarterly results reported net sales and profit for December 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 1 Cr (Quarterly Results - Dec 2025)<BR>- Net Profit: 0 Cr (Quarterly Results - Dec 2025)<BR>- Market-cap: INR 5 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: N/A<BR>- Industry P/E: 67<BR>- Dividend Yield: 0.00%<BR>- Debt-Equity: -0.09<BR>- Return on Equity: -3.78%<BR>- Price to Book: 0.26<BR><BR>Contact Details:<BR>No Company Details Available.

Who are the peers of the Gian Lifecare?

Gian Lifecare's peers include Samsrita Labs, Transgene Biotek, Vanta Bioscience, Dhanvantri Jeev., Family Care, Clinitech Lab, Dr Lalchand. Lab, and Ashram Online. Dhanvantri Jeev. shows the highest 1-year return at 26.19%, while Gian Lifecare has a return of -67.47%.

Peers: The peers of Gian Lifecare are Samsrita Labs, Transgene Biotek, Vanta Bioscience, Dhanvantri Jeev., Family Care, Looks Health, Clinitech Lab, Dr Lalchand. Lab, and Ashram Online.<BR><BR>Quality Snapshot: Excellent management risk is observed at Family Care, while Below Average management risk is found at Vanta Bioscience, Dhanvantri Jeev., Clinitech Lab, Dr Lalchand. Lab, and the rest. Average growth is noted at Family Care, while Below Average growth is seen at Vanta Bioscience, Dhanvantri Jeev., Clinitech Lab, Dr Lalchand. Lab, and the rest. Good capital structure is present at Dhanvantri Jeev., Clinitech Lab, Dr Lalchand. Lab, and Gian Lifecare, while the rest do not qualify.<BR><BR>Return Snapshot: Dhanvantri Jeev. has the highest 1-year return at 26.19%, while Family Care has the lowest at -52.09%, with Gian Lifecare's 1-year return at -67.47% being lower than both. Additionally, several peers, including Samsrita Labs, Transgene Biotek, Vanta Bioscience, Family Care, Clinitech Lab, and Dr Lalchand. Lab, have negative six-month returns.

How big is Gian Lifecare?

As of 31st August, Gian Lifecare Ltd has a market capitalization of 5.00 Cr and reported Net Sales of 3.76 Cr with a Net Profit loss of 0.96 Cr over the latest four quarters. Shareholder's Funds are 19.23 Cr and Total Assets are 35.93 Cr as of March 2025.

As of 31st August, Gian Lifecare Ltd has a market capitalization of 5.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Gian Lifecare reported Net Sales of 3.76 Cr. However, the company experienced a loss of 0.96 Cr in Net Profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025. Shareholder's Funds stand at 19.23 Cr, while Total Assets are valued at 35.93 Cr.

Should I buy, sell or hold Gian Lifecare Ltd?

When is the next results date for Gian Lifecare Ltd?

The next results date for Gian Lifecare Ltd is 21 February 2026.

The next results date for Gian Lifecare Ltd is scheduled for 21 February 2026.

Is Gian Lifecare overvalued or undervalued?

As of September 4, 2025, Gian Lifecare is considered overvalued with a PE ratio of -14.79 and a year-to-date return of -23.94%, significantly underperforming compared to its peers and the overall market.

As of 4 September 2025, Gian Lifecare's valuation grade has moved from very attractive to very expensive, indicating a significant shift in its market perception. The company is currently overvalued, as evidenced by its PE ratio of -14.79, a Price to Book Value of 0.77, and an EV to EBITDA of 13.68. These metrics suggest that the stock is not only trading at a high valuation relative to its earnings but also reflects a concerning financial position with negative earnings.<BR><BR>In comparison to its peers, Gian Lifecare's valuation stands out unfavorably. For instance, Max Healthcare has a PE ratio of 93.55, while Apollo Hospitals maintains a PE of 72.11, both indicating a more robust earnings outlook. Additionally, the company's recent stock performance has been poor, with a year-to-date return of -23.94%, contrasting sharply with the Sensex's positive return of 3.30% over the same period. This further reinforces the notion that Gian Lifecare is currently overvalued in the healthcare services sector.

Are Gian Lifecare latest results good or bad?

Gian Lifecare's latest results show a 108.33% increase in net profit but a 21.62% decline in net sales, indicating mixed performance. The decreased performance score and a 'Strong Sell' recommendation suggest caution for investors.

Gian Lifecare's latest financial results indicate a mixed performance. While the company reported a significant increase in consolidated net profit of 108.33% compared to the previous quarter, net sales saw a decline of 21.62%. This flat overall performance suggests that while profitability has improved, the drop in sales raises concerns about the company's growth trajectory.<BR><BR>Additionally, the performance score has decreased from 6 to 0, which reflects a notable shift in its financial standing and may indicate operational challenges. The stock call of 'Strong Sell' from MarketsMOJO further suggests a cautious outlook on the company's future performance.<BR><BR>In summary, while there are some positive signs in terms of profit, the overall results are concerning, and investors should approach with caution.

How has been the historical performance of Gian Lifecare?

Gian Lifecare has experienced significant declines in net sales and profitability from Mar'22 to Mar'25, with net sales dropping from 15.93 Cr to 6.63 Cr and profit after tax turning negative at -0.04 Cr. Despite these challenges, total assets and liabilities increased, indicating a growing financial base.

Answer:<BR>The historical performance of Gian Lifecare has shown significant fluctuations over the years, particularly in its net sales and profitability metrics.<BR><BR>Breakdown:<BR>Gian Lifecare's net sales decreased from 15.93 Cr in Mar'22 to 6.63 Cr in Mar'25, reflecting a downward trend over the years, with a notable drop from 13.12 Cr in Mar'24. Total operating income followed a similar pattern, declining from 15.93 Cr in Mar'22 to 6.63 Cr in Mar'25. The company's total expenditure also decreased, from 9.90 Cr in Mar'22 to 5.72 Cr in Mar'25. Operating profit (PBDIT) saw a significant decline, dropping from 6.54 Cr in Mar'22 to 1.17 Cr in Mar'25, with a corresponding decrease in profit before tax from 5.85 Cr in Mar'22 to just 0.04 Cr in Mar'25. Consequently, profit after tax turned negative in Mar'25 at -0.04 Cr, down from 4.15 Cr in Mar'24 and 4.37 Cr in Mar'22. The company's earnings per share (EPS) also reflected this decline, falling to -0.04 in Mar'25 from 4.01 in Mar'24. On the balance sheet, total liabilities increased from 23.06 Cr in Mar'22 to 32.64 Cr in Mar'24, while total assets rose from 23.06 Cr in Mar'22 to 32.64 Cr in Mar'24, indicating a growing financial base despite the declining profitability. Cash flow from operating activities remained at 0.00 Cr in Mar'24, with closing cash and cash equivalents stable at 5.00 Cr. Overall, Gian Lifecare's performance has been marked by declining revenues and profits, alongside an increase in liabilities.

Who are the top shareholders of the Gian Lifecare?

The top shareholders of Gian Lifecare include Arun Kumar Gupta with 28.89%, individual investors holding 56.62%, and Shield Multistate Cooperative Credit with 6.49%. There are no mutual funds or foreign institutional investors involved, and 62.27% of promoter holdings are pledged.

The top shareholders of Gian Lifecare include Arun Kumar Gupta, who is the promoter with the highest holding at 28.89%. The company has a significant portion of its shares held by individual investors, totaling 56.62%. Additionally, the highest public shareholder is Shield Multistate Cooperative Credit, which holds 6.49% of the shares. It's important to note that there are no mutual funds or foreign institutional investors holding shares in the company, and the pledged promoter holdings stand at 62.2704%.

What is the technical trend for Gian Lifecare?

As of June 4, 2025, Gian Lifecare's trend is bearish with moderate strength, supported by bearish indicators across multiple time frames, despite some mixed signals from the MACD and KST.

As of 4 June 2025, the technical trend for Gian Lifecare has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. The weekly MACD indicates a mildly bullish signal, but the monthly MACD is bearish, suggesting a divergence in momentum. The Bollinger Bands are bearish on both weekly and monthly time frames, reinforcing the negative outlook. Daily moving averages are also bearish, indicating a downward trend in the short term. The KST shows a mildly bullish signal on the weekly chart, but is bearish monthly, which adds to the mixed signals. Overall, the bearish trend is supported by the recent price action and the longer-term performance, with the stock down 21.95% over the past year compared to a 7.50% increase in the Sensex.

What is the bonus history of the Gian Lifecare?

Gian Lifecare issued a bonus in a 6:5 ratio, with an ex-date of March 29, 2022, and a record date of March 30, 2022, making shareholders on record eligible for the bonus shares.

Gian Lifecare has a bonus history that includes a notable issue announced with a ratio of 6:5. This bonus was issued with an ex-date of March 29, 2022, and the record date was set for March 30, 2022. This means that shareholders on record as of the record date were eligible to receive the bonus shares. If you have any more questions about Gian Lifecare or its financial activities, feel free to ask!

Has Gian Lifecare declared dividend?

No Dividend History Available